

Hannah K Knudsen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2460510/publications.pdf>

Version: 2024-02-01

94
papers

3,805
citations

109321

35
h-index

138484

58
g-index

95
all docs

95
docs citations

95
times ranked

2318
citing authors

#	ARTICLE	IF	CITATIONS
1	Community coalition and key stakeholder perceptions of the community opioid epidemic before an intensive community-level intervention. <i>Journal of Substance Abuse Treatment</i> , 2022, 138, 108731.	2.8	12
2	The effect of Medicaid expansion on state-level utilization of buprenorphine for opioid use disorder in the United States. <i>Drug and Alcohol Dependence</i> , 2022, 232, 109336.	3.2	6
3	The Setting-Intervention Fit of Nine Evidence-Based Interventions for Substance Use Disorders Within HIV Service Organizations Across the United States: Results of a National Stakeholder-Engaged Real-Time Delphi Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2022, 90, S206-S214.	2.1	2
4	Adaptation of a standard extended-release naltrexone (XR-NTX) protocol for rural re-entering offenders with OUD. <i>Health and Justice</i> , 2021, 9, 4.	2.1	2
5	Resilience-Focused HIV Care to Promote Psychological Well-Being During COVID-19 and Other Catastrophes. <i>Frontiers in Public Health</i> , 2021, 9, 705573.	2.7	4
6	The Prevalence and Negative Impacts of Substance Use Disorders among People with HIV in the United States: A Real-Time Delphi Survey of Key Stakeholders. <i>AIDS and Behavior</i> , 2021, , 1.	2.7	12
7	Using conjoint analysis to study health policy changes: An example from a cohort of persons who use drugs. <i>International Journal of Drug Policy</i> , 2021, 98, 103425.	3.3	4
8	Prescribers' satisfaction with delivering medications for opioid use disorder. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2021, 16, 78.	2.2	0
9	Recent Increase in Methamphetamine Use in a Cohort of Rural People Who Use Drugs: Further Evidence for the Emergence of Twin Epidemics. <i>Frontiers in Psychiatry</i> , 2021, 12, 805002.	2.6	8
10	Adoption of the 275-Patient Buprenorphine Treatment Waiver for Treating Opioid Use Disorder: A State-Level Longitudinal Analysis. <i>Substance Abuse</i> , 2020, 41, 259-268.	2.3	16
11	Model and approach for assessing implementation context and fidelity in the HEALing Communities Study. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108330.	3.2	22
12	Longitudinal trends in nonmedical prescription opioid use in a cohort of rural Appalachian people who use drugs. <i>Preventive Medicine</i> , 2020, 140, 106194.	3.4	5
13	Organizational Facilitators and Barriers to Medication for Opioid Use Disorder Capacity Expansion and Use. <i>Journal of Behavioral Health Services and Research</i> , 2020, 47, 439-448.	1.4	15
14	The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. <i>Drug and Alcohol Dependence</i> , 2020, 217, 108335.	3.2	50
15	Substance use prevention services in juvenile justice and behavioral health: results from a national survey. <i>Health and Justice</i> , 2020, 8, 11.	2.1	12
16	Physicians' satisfaction with providing buprenorphine treatment. <i>Addiction Science & Clinical Practice</i> , 2019, 14, 34.	2.6	9
17	US physicians' decision-making during buprenorphine-naloxone treatment: Conjoint analyses of dose and office visit adjustments based on patient progress. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107490.	3.2	6
18	Impact of health reform on health insurance status among persons who use opioids in eastern Kentucky: A prospective cohort analysis. <i>International Journal of Drug Policy</i> , 2019, 70, 8-14.	3.3	4

#	ARTICLE	IF	CITATIONS
19	Pharmacotherapy, Resource Needs, and Physician Recruitment Practices in Substance Use Disorder Treatment Programs. <i>Journal of Addiction Medicine</i> , 2019, 13, 28-34.	2.6	8
20	Physicians as Mediators of Health Policy: Acceptance of Medicaid in the Context of Buprenorphine Treatment. <i>Journal of Behavioral Health Services and Research</i> , 2019, 46, 151-163.	1.4	17
21	Perceived need and availability of psychosocial interventions across buprenorphine prescriber specialties. <i>Addictive Behaviors</i> , 2019, 93, 72-77.	3.0	14
22	Physicians'™ Decision-making When Implementing Buprenorphine With New Patients: Conjoint Analyses of Data From a Cohort of Current Prescribers. <i>Journal of Addiction Medicine</i> , 2018, 12, 31-39.	2.6	16
23	Implementation of smoking cessation treatment in substance use disorder treatment settings: a review. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 215-225.	2.1	68
24	Author's™ response: smoking cessation treatment in substance use disorder settings. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 624-624.	2.1	0
25	Perceived Impacts of the Affordable Care Act: Perspectives of Buprenorphine Prescribers. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 111-121.	1.7	3
26	Buprenorphine physician supply: Relationship with state-level prescription opioid mortality. <i>Drug and Alcohol Dependence</i> , 2017, 173, S55-S64.	3.2	34
27	Test of a workforce development intervention to expand opioid use disorder treatment pharmacotherapy prescribers: protocol for a cluster randomized trial. <i>Implementation Science</i> , 2017, 12, 135.	6.9	11
28	Effects of an Organizational Linkage Intervention on Inter-Organizational Service Coordination Between Probation/Parole Agencies and Community Treatment Providers. <i>Administration and Policy in Mental Health and Mental Health Services Research</i> , 2016, 43, 105-121.	2.1	30
29	Implementation of Network for the Improvement of Addiction Treatment (NIATx) Processes in Substance Use Disorder Treatment Centers. <i>Journal of Behavioral Health Services and Research</i> , 2016, 43, 354-365.	1.4	9
30	The Diffusion of Acamprosate for the Treatment of Alcohol Use Disorder: Results From a National Longitudinal Study. <i>Journal of Substance Abuse Treatment</i> , 2016, 62, 62-67.	2.8	2
31	Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: Data from a national sample of treatment organizations. <i>Substance Abuse</i> , 2016, 37, 230-237.	2.3	7
32	States'™ implementation of the Affordable Care Act and the supply of physicians waived to prescribe buprenorphine for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2015, 157, 36-43.	3.2	31
33	The Supply of Physicians Waivered to Prescribe Buprenorphine for Opioid Use Disorders in the United States: A State-Level Analysis. <i>Journal of Studies on Alcohol and Drugs</i> , 2015, 76, 644-654.	1.0	65
34	Juvenile Justice'™ Translational Research on Interventions for Adolescents in the Legal System (JJ-TRIALS): a cluster randomized trial targeting system-wide improvement in substance use services. <i>Implementation Science</i> , 2015, 11, 57.	6.9	62
35	Medicaid, Private Insurance, and the Availability of Smoking Cessation Interventions in Substance Use Disorder Treatment. <i>Psychiatric Services</i> , 2015, 66, 1213-1220.	2.0	8
36	Innovation Attributes and Adoption Decisions: Perspectives from Leaders of a National Sample of Addiction Treatment Organizations. <i>Journal of Substance Abuse Treatment</i> , 2015, 49, 1-7.	2.8	18

#	ARTICLE	IF	CITATIONS
37	The Transition to Medication Adoption in Publicly Funded Substance Use Disorder Treatment Programs: Organizational Structure, Culture, and Resources. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 476-485.	1.0	12
38	Dissemination, Adoption, and Implementation of Acamprosate for Treating Alcohol Use Disorders. <i>Journal of Studies on Alcohol and Drugs</i> , 2014, 75, 467-475.	1.0	17
39	Reducing risky relationships: a multisite randomized trial of a prison-based intervention for reducing HIV sexual risk behaviors among women with a history of drug use. <i>AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV</i> , 2014, 26, 1071-1079.	1.2	31
40	The relationship between Clinical Trial Network protocol involvement and quality of substance use disorder treatment. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 232-237.	2.8	5
41	Patient characteristics and availability of onsite non-rapid and rapid HIV testing in US substance use disorder treatment programs. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 120-125.	2.8	10
42	Sustainment of Smoking Cessation Programs in Substance Use Disorder Treatment Organizations. <i>Nicotine and Tobacco Research</i> , 2013, 15, 1060-1068.	2.6	31
43	Quality of clinical supervision and counselor emotional exhaustion: The potential mediating roles of organizational and occupational commitment. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 528-533.	2.8	35
44	Disparities in Access to Physicians and Medications for the Treatment of Substance Use Disorders Between Publicly and Privately Funded Treatment Programs in the United States. <i>Journal of Studies on Alcohol and Drugs</i> , 2013, 74, 258-265.	1.0	47
45	Medication-Assisted Treatment in Criminal Justice Agencies Affiliated with the Criminal Justice-Drug Abuse Treatment Studies (CJ-DATS): Availability, Barriers, and Intentions. <i>Substance Abuse</i> , 2012, 33, 9-18.	2.3	179
46	Financial Factors and the Implementation of Medications for Treating Opioid Use Disorders. <i>Journal of Addiction Medicine</i> , 2012, 6, 280-286.	2.6	28
47	The Employment of Nurses in Publicly Funded Substance Abuse Treatment Programs. <i>Journal of Addictions Nursing</i> , 2012, 23, 174-180.	0.4	3
48	Perceptions of the State Policy Environment and Adoption of Medications in the Treatment of Substance Use Disorders. <i>Psychiatric Services</i> , 2012, 63, 19-25.	2.0	25
49	Risky Relationships: Targeting HIV Prevention for Women Offenders. <i>AIDS Education and Prevention</i> , 2012, 24, 339-349.	1.1	29
50	Physicians in the substance abuse treatment workforce: Understanding their employment within publicly funded treatment organizations. <i>Journal of Substance Abuse Treatment</i> , 2012, 43, 152-160.	2.8	9
51	Timing of buprenorphine adoption by privately funded substance abuse treatment programs: The role of institutional and resource-based interorganizational linkages. <i>Journal of Substance Abuse Treatment</i> , 2012, 42, 16-24.	2.8	12
52	The Implementation of Smoking Cessation Counseling in Substance Abuse Treatment. <i>Journal of Behavioral Health Services and Research</i> , 2012, 39, 28-41.	1.4	35
53	Using medication-assisted treatment for substance use disorders: Evidence of barriers and facilitators of implementation. <i>Addictive Behaviors</i> , 2011, 36, 584-589.	3.0	133
54	Availability of nicotine replacement therapy in substance use disorder treatment: Longitudinal patterns of adoption, sustainability, and discontinuation. <i>Drug and Alcohol Dependence</i> , 2011, 118, 244-250.	3.2	27

#	ARTICLE	IF	CITATIONS
55	Nurse turnover in substance abuse treatment programs affiliated with the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 307-312.	2.8	11
56	A Longitudinal Examination of Alcohol Pharmacotherapy Adoption in Substance Use Disorder Treatment Programs: Patterns of Sustainability and Discontinuation. <i>Journal of Studies on Alcohol and Drugs</i> , 2011, 72, 669-677.	1.0	29
57	Adoption and Implementation of Medications in Addiction Treatment Programs. <i>Journal of Addiction Medicine</i> , 2011, 5, 21-27.	2.6	156
58	Barriers to the implementation of medication-assisted treatment for substance use disorders: The importance of funding policies and medical infrastructure. <i>Evaluation and Program Planning</i> , 2011, 34, 375-381.	1.6	107
59	Facilitating Factors and Barriers to the Use of Medications in Publicly Funded Addiction Treatment Organizations. <i>Journal of Addiction Medicine</i> , 2010, 4, 99-107.	2.6	46
60	Counselor Attitudes toward the Use of Motivational Incentives in Addiction Treatment. <i>American Journal on Addictions</i> , 2010, 19, 496-503.	1.4	42
61	Substance Abuse Treatment Counselors and Tobacco Use: A Comparison of Comprehensive and Indoor-Only Workplace Smoking Bans. <i>Nicotine and Tobacco Research</i> , 2010, 12, 1151-1155.	2.6	16
62	The implementation of tobacco-related brief interventions in substance abuse treatment: A national study of counselors. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 212-219.	2.8	45
63	A longitudinal study of organizational formation, innovation adoption, and dissemination activities within the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S44-S52.	2.8	56
64	The adoption of alcohol pharmacotherapies in the Clinical Trials Network: The influence of research network participation. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, 275-283.	2.8	36
65	Structural and Cultural Barriers to the Adoption of Smoking Cessation Services in Addiction Treatment Organizations. <i>Journal of Addictive Diseases</i> , 2010, 29, 294-305.	1.3	67
66	Smoking Cessation Services in Adolescent Substance Abuse Treatment: Opportunities Missed?. <i>Journal of Drug Issues</i> , 2009, 39, 257-276.	1.2	6
67	Addiction Nursing and the Quality of Adolescent Substance Abuse Treatment. <i>Journal of Addictions Nursing</i> , 2009, 20, 169-171.	0.4	3
68	Examination of an interventionist-led HIV intervention among criminal justice-involved female prisoners. <i>Journal of Experimental Criminology</i> , 2009, 5, 245-272.	2.9	17
69	Adolescent-only substance abuse treatment: Availability and adoption of components of quality. <i>Journal of Substance Abuse Treatment</i> , 2009, 36, 195-204.	2.8	46
70	Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2009, 37, 307-312.	2.8	49
71	Modified Therapeutic Communities and Adherence to Traditional Elements. <i>Journal of Psychoactive Drugs</i> , 2009, 41, 275-283.	1.7	34
72	Racial and Ethnic Composition as a Correlate of Medication Availability within Addiction Treatment Organizations. <i>Sociological Focus</i> , 2009, 42, 133-151.	0.4	17

#	ARTICLE	IF	CITATIONS
73	Turnover intention and emotional exhaustion "at the top": Adapting the job demands-resources model to leaders of addiction treatment organizations.. Journal of Occupational Health Psychology, 2009, 14, 84-95.	3.3	111
74	Drug Abuse Treatment Beyond Prison Walls. Addiction Science & Clinical Practice, 2009, 5, 24-30.	2.6	25
75	Clinical supervision, emotional exhaustion, and turnover intention: A study of substance abuse treatment counselors in the Clinical Trials Network of the National Institute on Drug Abuse. Journal of Substance Abuse Treatment, 2008, 35, 387-395.	2.8	126
76	Partner Relationships and HIV Risk Behaviors Among Women Offenders. Journal of Psychoactive Drugs, 2008, 40, 471-481.	1.7	37
77	The Use of Antidepressant Medications in Substance Abuse Treatment: The Public-Private Distinction, Organizational Compatibility, and the Environment. Journal of Health and Social Behavior, 2007, 48, 195-210.	4.8	73
78	Racial and Ethnic Disparities in SSRI Availability in Substance Abuse Treatment. Psychiatric Services, 2007, 58, 55-62.	2.0	24
79	The adoption of medications in substance abuse treatment: Associations with organizational characteristics and technology clusters. Drug and Alcohol Dependence, 2007, 87, 164-174.	3.2	85
80	Innovation adoption in substance abuse treatment: Exposure, trialability, and the Clinical Trials Network. Journal of Substance Abuse Treatment, 2007, 32, 321-329.	2.8	103
81	Research participation and turnover intention: An exploratory analysis of substance abuse counselors. Journal of Substance Abuse Treatment, 2007, 33, 211-217.	2.8	48
82	EMOTIONAL EXHAUSTION AND TURNOVER INTENTION IN HUMAN SERVICE OCCUPATIONS: THE PROTECTIVE ROLE OF COWORKER SUPPORT. Sociological Spectrum, 2007, 28, 81-104.	1.9	182
83	Counselor Turnover in Substance Abuse Treatment Centers: An Organizational-Level Analysis. Sociological Inquiry, 2007, 77, 166-193.	2.0	45
84	Research Network Involvement and Addiction Treatment Center Staff: Counselor Attitudes toward Buprenorphine. American Journal on Addictions, 2007, 16, 365-371.	1.4	47
85	Service Delivery in Substance Abuse Treatment: Reexamining "Comprehensive" Care. Journal of Behavioral Health Services and Research, 2007, 34, 121-136.	1.4	69
86	Early adoption of buprenorphine in substance abuse treatment centers: Data from the private and public sectors. Journal of Substance Abuse Treatment, 2006, 30, 363-373.	2.8	120
87	Counselor emotional exhaustion and turnover intention in therapeutic communities. Journal of Substance Abuse Treatment, 2006, 31, 173-180.	2.8	114
88	Patterns of organization and management in private and public substance abuse treatment programs. Journal of Substance Abuse Treatment, 2006, 31, 235-243.	2.8	74
89	Trends in the Adoption of Medications for Alcohol Dependence. Journal of Clinical Psychopharmacology, 2006, 26, S13-S19.	1.4	73
90	Does service diversification enhance organizational survival?. Journal of Behavioral Health Services and Research, 2005, 32, 241-252.	1.4	18

#	ARTICLE	IF	CITATIONS
91	Organizational Predictors of Pharmacological Innovation Adoption: The Case of Disulfiram. Journal of Drug Issues, 2005, 35, 559-573.	1.2	32
92	Buprenorphine diffusion: the attitudes of substance abuse treatment counselors. Journal of Substance Abuse Treatment, 2005, 29, 95-106.	2.8	112
93	Modeling the use of innovations in private treatment organizations: The role of absorptive capacity. Journal of Substance Abuse Treatment, 2004, 26, 51-59.	2.8	129
94	Retaining counseling staff at substance abuse treatment centers: effects of management practices. Journal of Substance Abuse Treatment, 2003, 24, 129-135.	2.8	114